2 September 2021, Utrecht (The Netherlands) – Hubrecht Organoid Technology (HUB) joins a new international consortium of academic and industrial leaders in the field of cancer research which launches “PERSIST-SEQ”, a five-year public-private collaborative research program that aims to unravel drug resistance and develop smarter therapeutic strategies to treat cancer and prevent resistance. PERSIST-SEQ will provide the cancer research community with a new gold standard workflow for single-cell sequencing by developing and validating best practices as well as generating and analysing high-quality data. The program is funded by the Innovative Medicines Initiative (IMI), and led by the Oncode Institute and AstraZeneca.


Have any questions?

contact us